Patient-Focused Drug Development High On Industry’s List Of PDUFA VI Tweaks
Executive Summary
BIO and PhRMA want patient input gathered through a more structured and data-driven process than the current disease area meetings under PDUFA V, which are “anecdotal” in nature; National Organization for Rare Disorders seeks an interactive portal between patient community and FDA reviewers.
You may also be interested in...
US FDA Patient Affairs Office Could Accelerate Involvement With 'Central Entry Point'
FDA floats idea of central office to coordinate patient engagement for symbolic as well as practical reasons.
FDA’s Structured Benefit-Risk Assessment Framework To Come Online In FY 2014
Drug reviews will include a benefit-risk summary assessment that states the rationale for regulatory action on a drug or biologic application and explains how differences of opinion among reviewers were resolved.
Rare Diseases: CBER Looks To ‘Lean Into’ Accelerated Approval, Align More With CDER
US FDA biologics center officials spoke about their efforts to increase collaboration and harmonization with the drugs center, and to internally involve more review disciplines in evaluating biomarker evidence, during a Reagan-Udall Foundation meeting that weighed potential use of accelerated approval for neuronopathic mucopolysaccharidoses disorders.